Selective overexpression of Comt in prefrontal cortex rescues schizophrenia-like phenotypes in a mouse model of 22q11 deletion syndrome

Translational Psychiatry

Volumn 2, Issue , 2012, Pages

  Kimoto, S ^a,b   Muraki, K ^a   Toritsuka, M ^a,b   Mugikura, S ^c   Kajiwara, K ^c   Kishimoto, T ^b   Illingworth, E ^d   Tanigaki, K ^a  

^a Shiga Medical Center   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

^c TOKAI UNIVERSITY   (Japan)

^d UNIVERSITY OF SALERNO   (Italy)

Author keywords

22q11 deletion syndrome; Comt; interneuron; mouse models; schizophrenia

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 4 AMINOBUTYRIC ACID A RECEPTOR BETA2; 6 FLUORO 2,9 DIHYDRO 9 METHYL 2 PHENYL 4 (1 PYRROLIDINYLCARBONYL) 1H PYRIDO[3,4 B]INDOL 1 ONE; BRETAZENIL; CATECHOL METHYLTRANSFERASE; DIZOCILPINE; GLUTAMATE DECARBOXYLASE 65; L 655708; LENTIVIRUS VECTOR; METHAMPHETAMINE; REELIN; TOLCAPONE; UNCLASSIFIED DRUG; ZOLPIDEM; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; BENZODIAZEPINE DERIVATIVE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

4 AMINOBUTYRIC ACID RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHROMOSOME DELETION 22Q11; CONTROLLED STUDY; GABAERGIC SYSTEM; GENE OVEREXPRESSION; INTERNEURON; MALE; MOUSE; NONHUMAN; PHENOTYPE; PREFRONTAL CORTEX; PROTEIN EXPRESSION; SCHIZOPHRENIA; TREATMENT RESPONSE; ANIMAL; DIGEORGE SYNDROME; DISEASE MODEL; DRUG ANTAGONISM; ENZYMOLOGY; GENE EXPRESSION; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; MOUSE MUTANT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BENZODIAZEPINONES; CATECHOL O-METHYLTRANSFERASE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIGEORGE SYNDROME; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGONISTS; GABA-A RECEPTOR AGONISTS; GAMMA-AMINOBUTYRIC ACID; GENE EXPRESSION; MICE; MICE, KNOCKOUT; PREFRONTAL CORTEX; RECEPTORS, N-METHYL-D-ASPARTATE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SCHIZOPHRENIA;

EID: 84874303716     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2012.70     Document Type: Article

References (55)

1. Pulver AE, Nestadt G, Goldberg R, Shprintzen RJ, Lamacz M, Wolyniec PS et al. Psychotic illness in patients diagnosed with velo-cardio-facial syndrome and their relatives. J Nerv Ment Dis 1994; 182: 476-478.
2. Karayiorgou M, Morris MA, Morrow B, Shprintzen RJ, Goldberg R, Borrow J et al. Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. Proc Natl Acad Sci USA 1995; 92: 7612-7616.
3. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ et al. Finding the missing heritability of complex diseases. Nature 2009; 461: 747-753.
4. Puech A, Saint-Jore B, Funke B, Gilbert DJ, Sirotkin H, Copeland NG et al. Comparative mapping of the human 22q11 chromosomal region and the orthologous region in mice reveals complex changes in gene organization. Proc Natl Acad Sci USA 1997; 94: 14608-14613.
5. Paylor R, McIlwain KL, McAninch R, Nellis A, Yuva-Paylor LA, Baldini A et al. Mice deleted for the DiGeorge/velocardiofacial syndrome region show abnormal sensorimotor gating and learning and memory impairments. Hum Mol Genet 2001; 10: 2645-2650.
6. Stark KL, Xu B, Bagchi A, Lai WS, Liu H, Hsu R et al. Altered brain microRNA biogenesis contributes to phenotypic deficits in a 22q11-deletion mouse model. Nat Genet 2008; 40: 751-760.
7. Paterlini M, Zakharenko SS, Lai WS, Qin J, Zhang H, Mukai J et al. Transcriptional and behavioral interaction between 22q11.2 orthologs modulates schizophrenia-related phenotypes in mice. Nat Neurosci 2005; 8: 1586-1594.
8. Scatton B, Dubois A, Dubocovich ML, Zahniser NR, Fage D. Quantitative autoradiography of 3H-nomifensine binding sites in rat brain. Life Sci 1985; 36: 815-822.
9. Sesack SR, Hawrylak VA, Matus C, Guido MA, Levey AI. Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci 1998; 18: 2697-2708.
10. Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, Pfaff D et al. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci USA 1998; 95: 9991-9996.
11. Moron JA, Brockington A, Wise RA, Rocha BA, Hope BT. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci 2002; 22: 389-395.
12. Miner LH, Schroeter S, Blakely RD, Sesack SR. Ultrastructural localization of the norepinephrine transporter in superficial and deep layers of the rat prelimbic prefrontal cortex and its spatial relationship to probable dopamine terminals. J Comp Neurol 2003; 466: 478-494.
13. Tunbridge E, Burnet PW, Sodhi MS, Harrison PJ. Catechol-o- methyltransferase (COMT) and proline dehydrogenase (PRODH) mRNAs in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and major depression. Synapse 2004; 51: 112-118.
14. Gothelf D, Eliez S, Thompson T, Hinard C, Penniman L, Feinstein C et al. COMT genotype predicts longitudinal cognitive decline and psychosis in 22q11.2 deletion syndrome. Nat Neurosci 2005; 8: 1500-1502.
15. Baker K, Baldeweg T, Sivagnanasundaram S, Scambler P, Skuse D. COMT Val108/158 Met modifies mismatch negativity and cognitive function in 22q11 deletion syndrome. Biol Psychiatry 2005; 58: 23-31.
16. Lachman HM, Morrow B, Shprintzen R, Veit S, Parsia SS, Faedda G et al. Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome. Am J Med Genet 1996; 67: 468-472.
17. Michaelovsky E, Gothelf D, Korostishevsky M, Frisch A, Burg M, Carmel M et al. Association between a common haplotype in the COMT gene region and psychiatric disorders in individuals with 22q11.2DS. Int J Neuropsychopharmacol 2008; 11: 351-363.
18. Kates WR, Antshel KM, Abdulsabur N, Colgan D, Funke B, Fremont W et al. A gender-moderated effect of a functional COMT polymorphism on prefrontal brain morphology and function in velo-cardio-facial syndrome (22q11.2 deletion syndrome). Am J Med Genet B Neuropsychiatr Genet 2006; 141B: 274-280.
19. Bearden CE, Jawad AF, Lynch DR, Sokol S, Kanes SJ, McDonald-McGinn DM et al. Effects of a functional COMT polymorphism on prefrontal cognitive function in patients with 22q11.2 deletion syndrome. Am J Psychiatry 2004; 161: 1700-1702.
20. Shashi V, Keshavan MS, Howard TD, Berry MN, Basehore MJ, Lewandowski E et al. Cognitive correlates of a functional COMT polymorphism in children with 22q11.2 deletion syndrome. Clin Genet 2006; 69: 234-238.
21. Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 1995; 376: 572-575.
22. Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci USA 2003; 100: 6186-6191.
23. Papaleo F, Crawley JN, Song J, Lipska BK, Pickel J, Weinberger DR et al. Genetic dissection of the role of catechol-O-methyltransferase in cognition and stress reactivity in mice. J Neurosci 2008; 28: 8709-8723.
24. Maynard TM, Haskell GT, Peters AZ, Sikich L, Lieberman JA, LaMantia AS. A comprehensive analysis of 22q11 gene expression in the developing and adult brain. Proc Natl Acad Sci USA 2003; 100: 14433-14438.
25. Stanwood GD, Parlaman JP, Levitt P. Anatomical abnormalities in dopaminoceptive regions of the cerebral cortex of dopamine D1 receptor mutant mice. J Comp Neurol 2005; 487: 270-282.
26. Kim SY, Choi KC, Chang MS, Kim MH, Kim SY, Na YS et al. The dopamine D2 receptor regulates the development of dopaminergic neurons via extracellular signal-regulated kinase and Nurr1 activation. J Neurosci 2006; 26: 4567-4576.
27. Earls LR, Bayazitov IT, Fricke RG, Berry RB, Illingworth E, Mittleman G et al. Dysregulation of presynaptic calcium and synaptic plasticity in a mouse model of 22q11 deletion syndrome. J Neurosci 2011; 30: 15843-15855.
28. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 2002; 295: 868-872.
29. Lahti AC, Koffel B, LaPorte D, Tamminga CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995; 13: 9-19.
30. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997; 17: 141-150.
31. Szeszko PR, Bilder RM, Dunlop JA, Walder DJ, Lieberman JA. Longitudinal assessment of methylphenidate effects on oral word production and symptoms in first-episode schizophrenia at acute and stabilized phases. Biol Psychiatry 1999; 45: 680-686.
32. Perry TL, Kish SJ, Buchanan J, Hansen S. Gamma-aminobutyric-acid deficiency in brain of schizophrenic patients. Lancet 1979; 1: 237-239.
33. Benes FM, Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 2001; 25: 1-27.
34. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 2005; 6: 312-324.
35. Xu B, Roos JL, Dexheimer P, Boone B, Plummer B, Levy S et al. Exome sequencing supports a de novo mutational paradigm for schizophrenia. Nat Genet 2011; 43: 864-868.
36. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991; 108: 193-199.
37. Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 1997; 154: 805-811.
38. Kargieman L, Santana N, Mengod G, Celada P, Artigas F. Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine. Proc Natl Acad Sci USA 2007; 104: 14843-14848.
39. Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney Jr WE et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 1995; 52: 258-266.
40. Volk DW, Austin MC, Pierri JN, Sampson AR, Lewis DA. Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch Gen Psychiatry 2000; 57: 237-245.
41. Lewis DA, Gonzalez-Burgos G. Pathophysiologically based treatment interventions in schizophrenia. Nat Med 2006; 12: 1016-1022.
42. Woo TU, Whitehead RE, Melchitzky DS, Lewis DA. A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proc Natl Acad Sci USA 1998; 95: 5341-5346.
43. Volk DW, Pierri JN, Fritschy JM, Auh S, Sampson AR, Lewis DA. Reciprocal alterations in pre-and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cereb Cortex 2002; 12: 1063-1070.
44. Volk D, Austin M, Pierri J, Sampson A, Lewis D. GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons. Am J Psychiatry 2001; 158: 256-265.
45. Meechan DW, Tucker ES, Maynard TM, LaMantia AS. Diminished dosage of 22q11 genes disrupts neurogenesis and cortical development in a mouse model of 22q11 deletion/DiGeorge syndrome. Proc Natl Acad Sci USA 2009; 106: 16434-16445.
46. Shifman S, Johannesson M, Bronstein M, Chen SX, Collier DA, Craddock NJ et al. Genome-wide association identifies a common variant in the reelin gene that increases the risk of schizophrenia only in women. PLoS Genet 2008; 4: e28.
47. Zhao C, Xu Z, Chen J, Yu Z, Tong KL, Lo WS et al. Two isoforms of GABA(A) receptor beta2 subunit with different electrophysiological properties: differential expression and genotypical correlations in schizophrenia. Mol Psychiatry 2006; 11: 1092-1105.
48. Campo CG, Sinagra M, Verrier D, Manzoni OJ, Chavis P. Reelin secreted by GABAergic neurons regulates glutamate receptor homeostasis. PLoS One 2009; 4: e5505.
49. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 2007; 27: 11496-11500.
50. Marenco S, Savostyanova AA, van der Veen JW, Geramita M, Stern A, Barnett AS et al. Genetic modulation of GABA levels in the anterior cingulate cortex by GAD1 and COMT. Neuropsychopharmacology 2010; 35: 1708-1717.
51. Harsing Jr LG, Zigmond MJ. Influence of dopamine on GABA release in striatum: evidence for D1-D2 interactions and non-synaptic influences. Neuroscience 1997; 77: 419-429.
52. Retaux S, Besson MJ, Penit-Soria J. Opposing effects of dopamine D2 receptor stimulation on the spontaneous and the electrically evoked release of [3H]GABA on rat prefrontal cortex slices. Neuroscience 1991; 42: 61-71.
53. Seamans JK, Gorelova N, Durstewitz D, Yang CR. Bidirectional dopamine modulation of GABAergic inhibition in prefrontal cortical pyramidal neurons. J Neurosci 2001; 21: 3628-3638.
54. Lewis DA, Cho RY, Carter CS, Eklund K, Forster S, Kelly MA et al. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am J Psychiatry 2008; 165:1585-1593.
55. Buchanan RW, Keefe RS, Lieberman JA, Barch DM, Csernansky JG, Goff DC et al. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry 2011; 69: 442-449.